Mark Oppe

4.2k total citations · 3 hit papers
72 papers, 3.1k citations indexed

About

Mark Oppe is a scholar working on Economics and Econometrics, General Health Professions and Sociology and Political Science. According to data from OpenAlex, Mark Oppe has authored 72 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Economics and Econometrics, 19 papers in General Health Professions and 16 papers in Sociology and Political Science. Recurrent topics in Mark Oppe's work include Health Systems, Economic Evaluations, Quality of Life (56 papers), Economic and Environmental Valuation (36 papers) and Delphi Technique in Research (16 papers). Mark Oppe is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (56 papers), Economic and Environmental Valuation (36 papers) and Delphi Technique in Research (16 papers). Mark Oppe collaborates with scholars based in Netherlands, United Kingdom and Spain. Mark Oppe's co-authors include Nancy Devlin, Juan Manuel Ramos-Goñi, Ágota Szende, Elly Stolk, Paul F. M. Krabbe, Oliver Rivero‐Arias, Koonal Shah, Ben van Hout, Frank de Charro and Nan Luo and has published in prestigious journals such as Social Science & Medicine, Medical Care and Quality of Life Research.

In The Last Decade

Mark Oppe

71 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EQ-5D value sets : inventory, comparative review, and user guide

2007 422 citations Ágota Szende, Mark Oppe et al. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) profile →
A Program of Methodological Research to Arrive at the New International EQ-5D-5L Valuation Protocol

2014 340 citations Mark Oppe, Nancy Devlin et al. Value in Health profile →
United States Valuation of EQ-5D-5L Health States Using an International Protocol

2019 251 citations A. Simon Pickard, Eleanor Pullenayegum et al. Value in Health profile →

Peers

Countries citing papers authored by Mark Oppe

Since Specialization

Citations

This map shows the geographic impact of Mark Oppe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Oppe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Oppe more than expected).

Fields of papers citing papers by Mark Oppe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Oppe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Oppe. The network helps show where Mark Oppe may publish in the future.

Co-authorship network of co-authors of Mark Oppe

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Oppe. A scholar is included among the top collaborators of Mark Oppe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Oppe. Mark Oppe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms 2021 ·The European Journal of Health Economics ·Koonal Shah, Bryan Bennett, (unknown), Louise Longworth, John Brazier, Mark Oppe, A. Simon Pickard, James W. Shaw	6
2	Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses 2021 ·The European Journal of Health Economics ·Mark Oppe, (unknown), (unknown), (unknown), Juan Manuel Ramos-Goñi	1
3	Cost-effectiveness of a home-based group educational programme on renal replacement therapies: a study protocol 2019 ·BMJ Open ·(unknown), Mark Oppe, (unknown), Jan J.V. Busschbach, Willem Weimar, Emma K. Massey, Sohal Y. Ismail	3
4	Toward a Smaller Design for EQ-5D-5L Valuation Studies 2019 ·Value in Health ·Zhihao Yang, Nan Luo, Mark Oppe, Gouke J. Bonsel, Jan J.V. Busschbach, Elly Stolk	17
5	Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective 2018 ·Value in Health ·Simone Kreimeier, Mark Oppe, Juan Manuel Ramos-Goñi, Amanda Cole, Nancy Devlin, Michael Herdman, Brendan Mulhern, Koonal Shah, Elly Stolk, Oliver Rivero‐Arias, Wolfgang Greiner	92
6	Quality Control Process for EQ-5D-5L Valuation Studies 2016 ·Value in Health ·Juan Manuel Ramos-Goñi, Mark Oppe, (unknown), Jan J.V. Busschbach, Elly Stolk	143
7	The Maps Reporting Statement for Studies Mapping onto Generic Preference-Based outcome Measures 2015 ·Value in Health ·Stavros Petrou, Oliver Rivero‐Arias, Helen Dakin, Louise Longworth, Mark Oppe, Robert Froud, Alastair Gray	2
8	PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT 2015 ·International Journal of Technology Assessment in Health Care ·Stavros Petrou, Oliver Rivero‐Arias, Helen Dakin, Louise Longworth, Mark Oppe, Robert Froud, Alastair Gray	6
9	A Five-Year Model to Assess The Cost-Effectiveness of New Diagnostic Tests In The Early Diagnosis of Rheumatoid Arthritis 2015 ·Value in Health ·(unknown), J. Luime, Mark Oppe, J. M. W. Hazes, Maureen Rutten‐van Mölken	1
10	Development of an Eq-5d Respiratory Bolt-on 2015 ·Value in Health ·Martine Hoogendoorn, (unknown), (unknown), Mark Oppe, (unknown), Maureen Rutten‐van Mölken	5
11	Learning and Satisficing: An Analysis of Sequence Effects in Health Valuation 2015 ·Value in Health ·Benjamin M. Craig, (unknown), Kim Rand, Juan Manuel Ramos-Goñi, Mark Oppe	17
12	Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement 2015 ·Journal of Medical Economics ·Stavros Petrou, Oliver Rivero‐Arias, Helen Dakin, Louise Longworth, Mark Oppe, Robert Froud, Alastair Gray	5
13	EQ-5D Portuguese population norms 2013 ·Quality of Life Research ·Lara Noronha Ferreira, Pedro Lopes Ferreira, Luís Nobre Pereira, Mark Oppe	84
14	SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis 2013 ·Health Technology Assessment ·Rob Riemsma, Maiwenn Al, Isaac Corro Ramos, (unknown), Nigel Armstrong, Gary Lee, Steve Ryder, Caro Noake, Marieke Krol, Mark Oppe, Jos Kleijnen, Hans Severens	39
15	Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best–worst scaling? 2013 ·The European Journal of Health Economics ·Feng Xie, Eleanor Pullenayegum, Kathryn Gaebel, Mark Oppe, Paul F. M. Krabbe	31
16	Lead versus lag time trade-off variants: does it make any difference? 2013 ·Value in Health ·Federico Augustovski, Lucila Rey‐Ares, Vilma Irazola, Mark Oppe, Nancy Devlin	1
17	PIH39 Eliciting Preferences to the EQ-5D-5L Health States: Discrete Choice Experiment or Multiprofile Case of Best-Worst Scaling 2012 ·Value in Health ·Feng Xie, E. Pullenayegum, Kathryn Gaebel, Mark Oppe, Paul F. M. Krabbe	2
18	Comparing Methods of Data Synthesis 2010 ·PharmacoEconomics ·Mark Oppe, Maiwenn Al, Maureen Rutten‐van Mölken	4
19	COST-EFFECTIVENESS OF PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) COMPARED WITH BSC ALONE IN CHEMOREFRACTORY METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH WILD-TYPE (WT) KRAS TUMOR STATUS IN THE NETHERLANDS 2008 ·Ghent University Academic Bibliography (Ghent University) ·Colin A. Graham, Rohit Borker, Mark Oppe, (unknown), Brittany Barber, Anita J. Brogan, (unknown), Marc Peeters, Giovanna Devercelli	3
20	EQ-5D value sets : inventory, comparative review, and user guide breakdown → 2007 ·Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) ·Ágota Szende, Mark Oppe, Nancy Devlin	422

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact